Citation Impact
Citing Papers
MicroRNA-7, a Homeobox D10 Target, Inhibits p21-Activated Kinase 1 and Regulates Its Functions
2008
A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6
2006
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
2012
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
2001
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
2005
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
2009
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
2005
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
2012
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
2015
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
2014
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
1998
Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
2009 StandoutNobel
A view on drug resistance in cancer
2019 StandoutNature
Biologic Characteristics of Interval and Screen-Detected Breast Cancers
2000
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
p53, the Cellular Gatekeeper for Growth and Division
1997 Standout
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
1998
MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
2014
Therapeutic Strategies for Targeting Ras Proteins
2011
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
2011
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
A microRNA component of the p53 tumour suppressor network
2007 StandoutNature
Imaging in the era of molecular oncology
2008 StandoutNature
Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual‐colour fluorescence in‐situ hybridization
2011
Genetic instabilities in human cancers
1998 StandoutNature
PI3K pathway alterations in cancer: variations on a theme
2008
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
2006
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
1996 StandoutNature
TRIBE: Hijacking an RNA-Editing Enzyme to Identify Cell-Specific Targets of RNA-Binding Proteins
2016 StandoutNobel
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation
2010
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
2015
CDK inhibitors in cancer therapy: what is next?
2007
Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines
2003
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Natural RNA circles function as efficient microRNA sponges
2013 StandoutNature
Perturbations of the AKT signaling pathway in human cancer
2005
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
The mighty mouse: genetically engineered mouse models in cancer drug development
2006
p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.
1996
Immunity, Inflammation, and Cancer
2010 Standout
Increased activated Akt expression in renal cell carcinomas and prognosis
2008
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
1996
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Unexpected Reduction of Skin Tumorigenesis on Expression of Cyclin-Dependent Kinase 6 in Mouse Epidermis
2011
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
2010
Cell cycle kinases in cancer
2007
Molecular portraits of human breast tumours
2000 StandoutNature
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
1999 StandoutNobel
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
1999
Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes
2013
Clonal evolution in cancer
2012 StandoutNature
Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
2008
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
1993 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
CDK Inhibitor p18INK4c Is a Downstream Target of GATA3 and Restrains Mammary Luminal Progenitor Cell Proliferation and Tumorigenesis
2009
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
2002
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
2011
Biological determinants of endocrine resistance in breast cancer
2009
Breast Tumor Characteristics as Predictors of Mammographic Detection: Comparison of Interval- and Screen-Detected Cancers
1999
The Requirement for Cyclin D Function in Tumor Maintenance
2012
Cdk2-Null Mice Are Resistant to ErbB-2-Induced Mammary Tumorigenesis
2011
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
2009 Standout
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
2013
Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research
2011
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
2010
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
The Bcl-2 Protein Family: Arbiters of Cell Survival
1998 StandoutScience
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
2010
Mechanisms of DNA Excision Repair
1994 StandoutScienceNobel
Cancer Cell Cycles
1996 StandoutScience
Cell Cycle Control and Cancer
1994 StandoutScienceNobel
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
2000
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
2001
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
1995 Standout
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery
2015
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
2000 StandoutScience
Post-Transcriptional Controls by Ribonucleoprotein Complexes in the Acquisition of Drug Resistance
2013
Cdk2 and Cdk4 Activities Are Dispensable for Tumorigenesis Caused by the Loss of p53
2009
Cancer Genome Landscapes
2013 StandoutScience
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
2006
Targeting CDK4 and CDK6: From Discovery to Therapy
2015
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
2015
Chemical Glycoproteomics
2016 StandoutNobel
Works of Olle Stål being referenced
Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
2009
Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer
1994
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
2002
Akt kinases in breast cancer and the results of adjuvant therapy
2003
Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program
1989
P53 Expression and the Result of Adjuvant Therapy of Breast Cancer
1995
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
2004
Requirement for CDK4 kinase function in breast cancer
2006
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
2000
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer
2007
Association Between Pak1 Expression and Subcellular Localization and Tamoxifen Resistance in Breast Cancer Patients
2006
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
2005
Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival
2008
Simultaneous analysis of c‐erbB‐2 expression and DNA content in breast cancer using flow cytometry
1994
Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF
2010
Interval cancers and cancers in non-attenders in the östergötland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence
1997
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
2009
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
2000
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
2012
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
2010
Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols
1995
S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer
1994
Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer
2006
Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification
2005
Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
2000
Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma
1992
PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer
2007